uniQure jumps 150% after AMT-130 posts 75% Huntington's slowdown - BLA targeted Q1 2026

uniQure (NASDAQ: QURE) jumped roughly 150% on Wednesday after releasing topline data from its pivotal Phase I/II program for AMT-130 in Huntington's disease. The move was one of those "get-out-your-notebook" moments: big, sudden and packed with implications for how the market prices biotech binary events.

The headline numbers are stark. High-dose AMT-130 hit the trial's primary endpoint, showing a 75% slowing of disease progression at 36 months on the composite Unified Huntington's Disease Rating Scale (cUHDRS) versus a propensity score-matched external control. A key secondary endpoint - Total Functional Capacity (TFC) - showed a 60% reduction in progression. Cognitive measures also favored the therapy: an 88% slowing on the Symbol Digit Modalities Test and a 113% slowing on Stroop Word Reading at the 36‑month mark. On the biomarker side, mean cerebrospinal fluid neurofilament light (CSF NfL), a marker tied to neurodegeneration, was 8.2% below baseline at three years.

Safety data were described as manageable. No new drug-related serious adverse events have surfaced since December 2022, and most of the commonly reported problems were linked to the administration procedure rather than the vector or transgene itself. Sarah Tabrizi, director of the UCL Huntington's Disease Centre, said the results showed statistically significant effects on both functional scales at 36 months and pointed to durable biomarker support.

Regulatory timeline now has teeth: uniQure (NASDAQ: QURE) plans to file a Biologics License Application in Q1 2026 and is eyeing a possible U.S. launch later that year if the FDA signs off. The program already carries Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations.

From a trading angle the announcement does a few predictable things. First, volume and volatility spiked as the market re-priced a formerly speculative name into one with a clear regulatory runway. Big percentage moves like this tend to pull in option players hunting gamma and force short-covering in names with crowded short interest. Second, the use of a propensity score-matched external control - rather than a randomized, placebo-controlled comparator - will keep debate alive among clinicians and regulators; that debate is a volatility generator in its own right. Lastly, operational hurdles remain: manufacturing scale-up for an intrastriatal gene therapy, long-term safety monitoring, pricing and reimbursement discussions - all of which can swing sentiment sharply over the next 12-18 months.

In plain terms: the market has re-rated the company overnight, but the calendar now matters more than ever. BLA filing in Q1 2026 is the next hard event to pencil into models. Will the FDA be satisfied with the evidence package built around external controls and three‑year data? That's the question moving the tape from here.